Trial Profile

Efficacy and safety trial of AJG533 with long term treatment in patients with chronic constipation

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elobixibat (Primary)
Indications Constipation
Focus Adverse reactions; Registrational
Sponsors Ajinomoto Pharma; Albireo AB; EA Pharma

Most Recent Events

09 Jul 2018 According to an Eisai Co Ltd media release, data from this trial has been published in The Lancet Gastroenterology & Hepatology, and was also presented at the Digestive Disease Week (DDW) 2018.
05 Jun 2018 Results determining the safety and efficacy of elobixibat for the treatment of chronic constipation from two trials (JapicCTI-153061 and JapicCTI-153062) presented at the Digestive Disease Week 2018
30 May 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com